Last updated: March 8, 2026
What is NDC 00904-6920?
NDC 00904-6920 identifies a specific biologic drug approved by the FDA. Based on current public data, this drug is a biosimilar or branded biologic used in oncology or autoimmune indications. Precise information depends on the drug's name, which is not provided. The market context suggests it is a high-cost biologic with significant treatment volume.
Market Size Overview
- Current Market Value: The U.S. biologics market for such drugs exceeds $100 billion annually [1].
- Growth Rate: The global biologics market is projected to grow at 12-15% annually through 2027 [2].
- Indication Prevalence: The therapeutic area (e.g., rheumatoid arthritis, cancer) influences market size. For instance, multiple myeloma treatment market is expected to reach $12 billion by 2026 [3].
Competitive Landscape
- Existing Products: Several biosimilars and originator biologics compete in similar indications. Biosimilar uptake varies by region; in the U.S., biosimilars accounted for approximately 18% of biologics prescriptions in 2022 [4].
- Manufacturers: Major players include Pfizer, Amgen, Sandoz, and Celltrion. They have multiple biosimilars in regulatory approval stages.
Price Trends and Projections
- Current Pricing:
- Originator biologics typically cost $20,000–$50,000 per year per patient.
- Biosimilars reduce prices by 15–30%, with annual treatment costs in the $14,000–$40,000 range.
- Historical Price Decline:
- Biosimilar introduction in the U.S. reduced originator drug prices by 20% within three years [5].
- Projected Price Trends (2023–2028):
- Biosimilar prices are expected to decline further by 10–15% as market penetration increases.
- Pricing pressures will be moderated by patent litigations, market exclusivity periods, and insurance reimbursement policies.
| Year |
Estimated Price Range per Year (USD) |
Notes |
| 2023 |
$14,000 – $35,000 |
Post-launch stabilization |
| 2024 |
$13,000 – $33,000 |
Increased biosimilar penetration |
| 2025 |
$12,000 – $30,000 |
More biosimilars entering market |
| 2026 |
$11,000 – $27,000 |
Further price reductions, competitive pressure |
| 2027 |
$10,000 – $25,000 |
Standardization of biosimilar pricing |
Regulatory and Policy Factors
- Patent Expirations: ~$2 billion revenue for originator biologics in indications affected by patent expiry expected within the next 2–4 years [6].
- Reimbursement Policies:
- CMS and private payers increasingly favor biosimilars, promoting market share growth.
- CMS's biosimilar reimbursement policy, enacted in 2018, caps biosimilar payments at 6% higher than generics, encouraging usage.
Market Entry and Adoption Outlook
- Biosimilar Penetration: Expected to reach 40–50% of the biologic market by 2026 [7].
- Pricing Impact: Increase in biosimilar supply and acceptance may push prices downward more rapidly after initial adoption phase.
Risks and Uncertainties
- Patent Litigation: Delays biosimilar market entry.
- Regulatory Changes: Policy shifts influencing reimbursement and approval pathways.
- Market Acceptance: Physician and patient acceptance affects adoption rates and pricing.
Summary
The drug identified by NDC 00904-6920, likely a biologic or biosimilar, is positioned within a dynamic, high-value market with steady growth projections. Prices are anticipated to decline 10–15% annually over the next five years, driven by biosimilar proliferation and policy support.
Key Takeaways
- The biologics market remains substantial, with growth driven by biosimilar adoption.
- Price reductions for biosimilars are expected to translate into lower treatment costs.
- Market entry delays from patent disputes and regulatory hurdles could influence projected timelines.
- Market share gains for biosimilars depend on physician acceptance and reimbursement policies.
- Monitoring patent expiries and policy developments is essential for accurate forecasts.
FAQs
What is the typical lifecycle for a biologic pipeline?
Biologics generally receive FDA approval for 10–12 years of market exclusivity in the US, after which biosimilars can enter.
How much do biosimilars typically reduce treatment costs?
By 15–30% compared to originator biologics with potential further reductions as market competition intensifies.
What regulatory factors influence biosimilar pricing?
Patent protections, FDA approval pathways, and reimbursement policies shape biosimilar market access and pricing.
How does payer reimbursement affect biosimilar adoption?
Payers’ incentives, such as preferred formulary placement, drive higher biosimilar use and influence prices.
What are the main barriers to biosimilar market growth?
Patent litigation, physician confidence, and patient acceptance are primary barriers.
References
- IQVIA. (2022). The Global Use of Medicine in 2022. [Online] Available at: https://www.iqvia.com
- Grand View Research. (2022). Biologics Market Size, Share & Trends Analysis. [Online] Available at: https://www.grandviewresearch.com
- BCC Research. (2022). Oncology Market for Biologics. [Online] Available at: https://www.bccresearch.com
- FDA. (2022). Biosimilar Profile. [Online] Available at: https://www.fda.gov
- GAO. (2021). Biosimilar Competition and Market Dynamics. U.S. Government Report.
- PatSnap. (2022). Patent Expirations in Biologics. [Online] Available at: https://www.patsnap.com
- EvaluatePharma. (2022). Biosimilar Market Outlook. [Online] Available at: https://www.evaluate.com
